151 related articles for article (PubMed ID: 6167110)
21. Treatment of palmoplantar psoriasis with monochromatic excimer light (308-nm) versus cream PUVA.
Neumann NJ; Mahnke N; Korpusik D; Stege H; Ruzicka T
Acta Derm Venereol; 2006; 86(1):22-4. PubMed ID: 16585984
[TBL] [Abstract][Full Text] [Related]
22. Increased cysteinyldopa plasma levels hint to melanocyte as stress sensor in psoriasis.
Panzella L; Wakamatsu K; Monfrecola G; Ito S; Ayala F; Napolitano A
Exp Dermatol; 2011 Mar; 20(3):288-90. PubMed ID: 21323749
[TBL] [Abstract][Full Text] [Related]
23. Urinary excretion of 5-S-cysteinyldopa in patients with primary melanoma or melanoma metastasis.
Agrup G; Agrup P; Andersson T; Falck B; Hansson J-A ; Jacobsson S; Rorsman H; Rosengrem A-M ; Rosengren E
Acta Derm Venereol; 1975; 55(5):337-41. PubMed ID: 52967
[TBL] [Abstract][Full Text] [Related]
24. The effectiveness of PUVA treatment in severe psoriasis is significantly increased by additional UV 308-nm excimer laser sessions.
Trott J; Gerber W; Hammes S; Ockenfels HM
Eur J Dermatol; 2008; 18(1):55-60. PubMed ID: 18086590
[TBL] [Abstract][Full Text] [Related]
25. 5-S-cysteinyldopa as a substrate for tyrosinase.
Hansson C; Rorsman H; Rosengren E
Acta Derm Venereol; 1980; 60(5):399-402. PubMed ID: 6162310
[TBL] [Abstract][Full Text] [Related]
26. Long-term safety of trioxsalen bath PUVA treatment: an 8-year follow-up of 149 psoriasis patients.
Berne B; Fischer T; Michaëlsson G; Norén P
Photodermatol; 1984 Feb; 1(1):18-22. PubMed ID: 6531278
[TBL] [Abstract][Full Text] [Related]
27. 8-MOP PUVA for psoriasis: a comparison of a minimal phototoxic dose-based regimen with a skin-type approach.
Collins P; Wainwright NJ; Amorim I; Lakshmipathi T; Ferguson J
Br J Dermatol; 1996 Aug; 135(2):248-54. PubMed ID: 8881668
[TBL] [Abstract][Full Text] [Related]
28. Plasma 5-S-cysteinyldopa concentrations in oculocutaneous albinism.
Nimmo JE; Hunter JA; Percy-Robb IW; Jay B; Phillips CI; Taylor WO
Acta Derm Venereol; 1985; 65(2):169-71. PubMed ID: 2408424
[TBL] [Abstract][Full Text] [Related]
29. Prostaglandins in PUVA-treated psoriasis.
Heiligstädt H; Kassis B; Weismann K; Søndergaad J
Acta Derm Venereol; 1978; 58(3):213-6. PubMed ID: 78634
[TBL] [Abstract][Full Text] [Related]
30. Diastereomers of 5-S-cysteinyldopa.
Agrup G; Edholm LE; Rorsman H; Rosengren E
Acta Derm Venereol; 1983; 63(1):59-61. PubMed ID: 6191491
[TBL] [Abstract][Full Text] [Related]
31. 5-S-cysteinyldopa in the urine of melanoma patients.
Agrup G; Agrup P; Andersson T; Falck B; Hansson JA; Jacobsson S; Rorsman H; Rosengren E; Rosengren AM
Acta Derm Venereol; 1977; 57(2):113-6. PubMed ID: 71802
[TBL] [Abstract][Full Text] [Related]
32. Itch following photochemotherapy for psoriasis.
Rogers S; Marks J; Shuster S
Acta Derm Venereol; 1981; 61(2):178-80. PubMed ID: 6165204
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of serum 5-S-cysteinyldopa for monitoring human metastatic melanoma during immunochemotherapy.
Wimmer I; Meyer JC; Seifert B; Dummer R; Flace A; Burg G
Cancer Res; 1997 Nov; 57(22):5073-6. PubMed ID: 9371505
[TBL] [Abstract][Full Text] [Related]
34. Improved method for analysis of cysteinyldopa in human serum.
Arstrand K; Kullman A; Andersson R; Rasmuson T; Kågedal B
Scand J Clin Lab Invest; 2004; 64(6):559-64. PubMed ID: 15370461
[TBL] [Abstract][Full Text] [Related]
35. 5-OH-dopa, product of and substrate for tyrosinase.
Agrup G; Rorsman H; Rosengren E
Acta Derm Venereol; 1982; 62(5):371-76. PubMed ID: 6183884
[TBL] [Abstract][Full Text] [Related]
36. Intracellular distribution of dopa and 5-S-cysteinyldopa in Harding-Passey melanoma.
Agrup G; Falck B; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1977; 57(4):313-5. PubMed ID: 70922
[TBL] [Abstract][Full Text] [Related]
37. [Treatment of plaque-type psoriasis with cream-PUVA therapy].
Steinmeyer K; Grundmann-Kollmann M; Podda M; Kaufmann R
Hautarzt; 2001 Oct; 52(10):885-7. PubMed ID: 17690819
[TBL] [Abstract][Full Text] [Related]
38. Urine excretion of 5-S-cysteinyldopa and serum sialic acid as tumor markers in human melanomas.
Marnot D; Decaux F; Berthelot P; Kalis B; Jardillier JC; Warren L
Cancer Detect Prev; 1983; 6(1-2):303-10. PubMed ID: 6411338
[TBL] [Abstract][Full Text] [Related]
39. Protein-bound dopa and 5-S-cysteinyldopa in non-melanogenic tissues.
Ito S; Jimbow K; Kato T; Kiyota M; Fujita K
Acta Derm Venereol; 1983; 63(6):463-7. PubMed ID: 6198833
[TBL] [Abstract][Full Text] [Related]
40. 5 years' experience of 5-S-cysteinyldopa in melanoma diagnosis.
Agrup G; Agrup P; Andersson T; Hafström L; Hansson C; Jacobsson S; Jönsson PE; Rorsman H; Rosengren AM; Rosengren E
Acta Derm Venereol; 1979; 59(5):381-8. PubMed ID: 93360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
